The global aneurysmal subarachnoid hemorrhage drugs market size was valued at $323.51 million in 2020, and is projected to reach $456.31 million by 2030, growing at a CAGR of 3.6% from 2021 to 2030. Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening type of stroke caused by bleeding in the area around the brain. The major factors that drive the growth of the global aSAH drugs market include surge in geriatric population and increase in population suffering from hypertension. Furthermore, lifestyle changes such as alcohol consumption and smoking increase risk of aSAH, which, in turn, propel the market growth.
Hypertension is one of the major factors that can lead to aSAH. As per the Centers for Disease Control and Prevention, about 70.0 million American adults suffer from high blood pressure, of which the condition of only 52.0% is under control. Moreover, according to the Centers for Medicare and Medicaid Services the U.S. healthcare expenditures grew from 4.6% to $3.8 trillion in 2019 and accounted for 17.7% of gross domestic product (GDP). In addition, the federal government accounted for 29 % of total health expenditures, followed by households with 28.4%. State and local governments accounted for 16.1% of total health care expenditures, while other private revenues accounted for 7.5%.
Furthermore, incidence of high blood pressure has increased, costing the U.S. $46.0 billion annually, which include the cost of healthcare services, medications to treat high blood pressure, and missed days of work.
In addition, increase in prevalence diseases such as stroke and hypertension and surge in geriatric population drive the growth of the aSAH drugs market. In addition, lifestyle changes, including increase in alcohol consumption and smoking rise the risk for aSAH, which, in turn, stimulates the market growth.
However, the associated side effects of drugs and medication taken during the treatment of aSAH restrain the aSAH drugs market share.
The aSAH drugs market is segmented on the basis of drug class and region. On the basis of drug class, the market is classified into opioid analgesic, calcium channel blocker, anticonvulsants, stool softeners, osmotic agents/diuretics, and other drugs. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA
Depending on drug class, the calcium channel blocker segment dominated the market and is expected to continue this trend during the forecast period, owing to increasing prevalence rate of cardiovascular diseases, changing lifestyle and hypertension. Rising assistance to people with anxiety disorders or bipolar disorder is also expected to help in the growth of the aneurysmal subarachnoid hemorrhage drugs market. In addition, increase patient awareness level, availability of the treatment options and vulnerable geriatric population are some of the influencing factors propelling the growth of the calcium channel blocker aSAH drugs market growth.
Region wise, North America dominated the market in 2020, owing to favorable healthcare infrastructure, which facilitated access to advanced aSAH drugs. In addition, government initiatives, including the Precision Medicine and Affordable Care Act, along with well-planned reimbursement policies, contributed to the market growth in North America. Moreover, surge in awareness among people and high purchasing parity resulted in increased demand for these devices. However, Asia-Pacific is expected to witness considerable market growth during the forecast period, due to rise in government support to enhance healthcare infrastructure. Economic developments in countries, including India and China, with higher disposable incomes fuel the demand for product. Moreover, China is expected to grow at high CAGR in, thereby making Asia-Pacific a aSAH drugs market opportunity.
The major companies profiled in this report include Azurity Pharmaceuticals, Johnson & Johnson, MediCure, NeurOp, Orexo AB, Pfizer, Inc., Pharmaxis, Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Vitrais, Inc.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current aSAH drugs market trends, estimations, and dynamics of the aneurysmal subarachnoid hemorrhage drugs market analysis from 2020 to 2030 to identify the prevailing aneurysmal subarachnoid hemorrhage drugs market opportunities.
- The aSAH Drugs Market analysis research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the aneurysmal subarachnoid hemorrhage drugs market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global aSAH drugs industry trends, key players, market segments, application areas, and market growth strategies.
Aneurysmal Subarachnoid Hemorrhage Drugs Market Report Highlights
| Aspects | Details |
 By Drug Class |
|
 By Region |
|
 Key Market Players | orexo ab, Sun Pharmaceutical Industries Ltd., NeurOp, Vitrais, Inc, Pharmaxis, Ltd., Azurity Pharmaceuticals, Johnson and Johnson, Pfizer, Inc., medicure, teva pharmaceutical industries ltd. |
Analyst Review
According to the analyst’s perspective, diseases such as hypertension and stroke constitute major proportion of health and economic concern across the globe; hence, the development of effective medication is the major necessity for their treatment.
The major factors that contribute to the market growth include change in lifestyle and rise in geriatric population. In addition, lifestyle changes that include surge in alcohol consumption and smoking rise the risk for aSAH, which accelerate the market growth. Along with this, surge in geriatric population are also prevailing the growth of the aneurysmal subarachnoid hemorrhage drugs market. However, associated side effects of the drugs are expected to restrain the market growth. In addition, need to create awareness about the optimal diagnosis and treatment of aneurysmal subarachnoid hemorrhage is expected to provide lucrative opportunities for the market growth.
North America is anticipated to dominate the aneurysmal subarachnoid hemorrhage drugs market throughout the forecast period, owing to increase in incidence of people suffering from hypertension, followed by Europe and Asia-Pacific.
The Aneurysmal Subarachnoid Hemorrhage Market is currently growing at a CAGR of 3.6% from 2021-2030.
Drug types such as Opioid Analgesic, Calcium Channel Blocker, Anticonvulsant, Stool Softener, Osmotic Agents/Diuretics which are off label drugs are used in treating Aneurysmal Subarachnoid Hemorrhage.
Estimated industry size of Aneurysmal Subarachnoid Hemorrhage Drugs Market is USD 323.5 Million in 2020
Largest regional market for Aneurysmal Subarachnoid Hemorrhage Drugs Market is North America.
Azurity Pharmaceuticals, Johnson and Johnson, MediCure, NeurOp, Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd.
Loading Table Of Content...
